HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife Nutrition Ltd.

https://www.herbalife.com/

Latest From Herbalife Nutrition Ltd.

US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results

Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.

Consumer Sales & Earnings

Herbalife Reports Second Straight Year Of Record Sales And Of Costs Climbing Due To Pandemic

Herbalife’s Asia-Pacific region led 2021 sales growth even as China sales continued to slide despite initiatives to boost business there. It reported record sales levels despite limits due to COVID-19 pandemic on shopping and other consumer activity while pandemic continues impacting supply and shipping costs and influenced 2022 earnings forecast.

Coronavirus COVID-19 Sales & Earnings

US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption

Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020.  More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.

Pricing Strategies Coronavirus COVID-19

Herbalife’s Asia-Pacific Region Stands Out As Most Others Fade In Year-Ago Comparison

Herbalife reports 46% growth in India fuels 11% sales increase to $393.5m for its Asia-Pacific region in Q3. Most regions had comparisons with year-ago quarter when pandemic stockpiling lifted sales.

Dietary Supplements Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
UsernamePublicRestriction

Register